XmAb564 / Xencor - LARVOL DELTA

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis (clinicaltrials.gov) - P1 | N=128 | Active, not recruiting | Sponsor: Xencor, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Activated Regulatory T Cells with a Highly Immunosuppressive Phenotype are Expanded by XmAb564, a Novel Potency-Optimized IL-2 Fc Fusion Protein (AAD 2024) - "XmAb564 selectively induced Tregs that co-expressed high levels of FoxP3, CD25 as well as LAG3/4-1BB/ICOS/TIGIT and peripheral elevations in IL-10, consistent with systemic immunosuppressive bioactivity."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis • FAS • FOXP3 • ICOS • IFNG • IL10 • IL2 • IL2RA • IL7R • ISG20 • LAG3 • TIGIT • TNFRSF9

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis (clinicaltrials.gov) - P1 | N=128 | Recruiting | Sponsor: Xencor, Inc.

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

XmAb564, a Novel Potency-Reduced IL-2 Fc Fusion Protein Selectively Expands Regulatory T cells: Results from a Single Ascending Dose Study in Healthy Adult Volunteers (EULAR 2023) - "Conclusion XmAb564 selectively induced Tregs and was well tolerated. XmAb564 PK and PD potentially supports extended multi-week dosing intervals and has a Treg induction magnitude and durability that may be competitive or superior to other candidates in clinic, providing the rationale for clinical evaluation across a broad range of inflammatory diseases."

Clinical • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • CD4 • CD8 • FOXP3 • IL2 • IL2RA • NCAM1

Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Xencor, Inc. | Recruiting ➔ Completed | Trial completion date: Jan 2024 ➔ Nov 2022 | Trial primary completion date: Dec 2023 ➔ Nov 2022

Trial completion • Trial completion date • Trial primary completion date

Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Xencor, Inc. | N=24 ➔ 48 | Trial completion date: Jun 2022 ➔ Jan 2024 | Trial primary completion date: May 2022 ➔ Dec 2023

Enrollment change • Trial completion date • Trial primary completion date

Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Xencor, Inc.

Clinical • New P1 trial